At this year’s Heath Ingredients Europe in Frankfurt, Arla Foods Ingredients will unveil a what they claim to be a highly innovative whey protein that is set to transform the fast-growing clinical nutrition category by offering companies the opportunity to create a 100% whey-based ready-to-drink beverage that is more effective, easier to formulate and better-tasting.
Lacprodan DI-7017 from Arla Foods Ingredients is a new generation of pure whey protein concentrate that is stable in ultra-high temperature (UHT) formulations at neutral pH, representing a genuine first in the market for clinical nutrition RTD beverages, which was worth almost €4 billion in the US & Europe in 2011.
Whey protein is notoriously hard to incorporate into UHT processes, which are widely used to manufacture clinical nutrition beverages with a long shelf life. As a result, manufacturers have until now tended to use alternative and less nutritionally effective proteins, such as casein, when formulating beverages for use in clinical nutrition.
Peter Schouw Andersen, Business Development Manager at Arla Foods Ingredients, said,
The benefits of whey protein over other sources of protein are well documented in the scientific literature, with studies demonstrating that whey protein passes through the gut more quickly than casein2,3 leading to faster gastric emptying and absorption of the protein. Whey also offers roughly twice the levels of muscle synthesis as casein4. Meanwhile, the amino acid profile in whey proteins covers or even exceeds the human requirements for essential amino acids, according to standards set by the World Health Organisation.
Source: Arla Foods Ingredients